

LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS,
Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B,
Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M,
Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML,
Osteoporosis-Pseudoglioma Syndrome Collaborative Group (2001) LDL
receptor-related protein 5 (LRP5) affects bone accrual and eye development. *Cell*
107: 513-23.

18. Kato M, Patel MS, Levasseur R, Lobov I, Chang BH, Glass 2nd DA, Hartmann C, Li L, Hwang TH, Brayton CF, Lang RA, Karsenty G, Chan L (2002) Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. *J Cell Biol* 157: 303-314.
19. Ezura Y, Nakajima T, Urano T, Sudo Y, Kajita M, Yoshida H, Suzuki T, Hosoi T, Inoue S, Shiraki M, Emi M (2007) Association of a single-nucleotide variation (A1330V) in the low-density lipoprotein receptor-related protein 5 gene (LRP5) with bone mineral density in adult Japanese women. *Bone* 40: 997-1005
20. Ferrari SL, Deutsch S, Baudoin C, Cohen-Solal M, Ostertag A, Antonarakis SE, Rizzoli R, de Verneuil MC (2005) LRP5 gene polymorphisms and idiopathic osteoporosis in men. LRP5 gene polymorphisms and idiopathic osteoporosis in men. *Bone* 37: 770-775

21. Ferrari SL, Deutsch S, Choudhury U, Chevalley T, Bonjour JP, Dermitzakis ET, Rizzoli R, Antonarakis SE (2004) Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size, and stature in whites. *Am J Hum Genet* 74: 866-875
22. Guo YF, Xiong DH, Shen H, Zhao LJ, Xiao P, Guo Y, Wang W, Yang TL, Recker RR, Deng HW (2006) Polymorphisms of the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with obesity phenotypes in a large family-based association study. *J Med Genet* 43: 798-803
23. Dessimoz J, Bonnard C, Huelsken J, Grapin-Botton A (2005) Pancreas-specific deletion of β -catenin reveals Wnt-dependent and Wnt-independent functions during development. *Curr Biol* 15: 1677-1683.
24. Heller RS, Dichmann DS, Jensen J, Miller C, Wong G, Madsen OD, Serup P (2002) Expression patterns of Wnts, Frizzleds, sFRPs, and misexpression in transgenic mice suggesting a role for Wnts in pancreas and foregut pattern formation. *Dev Dyn* 225: 260-270.
25. Rulifson IC, Karnik SK, Heiser PW, ten Berge D, Chen H, Gu X (2007) Wnt signaling regulates pancreatic beta cell proliferation. *Proc Natl Acad Sci USA* 104: 6247-6252.

Figure 1. Genomic organization of *LRP6* and pairwise LD analysis of SNPs. (A)

Schematic representation of the *LRP6* genomic region showing the locations of SNPs.

Coding and noncoding sequences of exons are shown as closed and open boxes, respectively. Details of the SNPs are provided in Table 1. (B) Values of D' (bold type) and of r^2 (nonbold type) for pairwise LD analysis in 92 control subjects. Three estimated LD blocks are highlighted in gray.

Figure 2. Genomic organization of *LRP5* and pairwise LD analysis of SNPs. (A)

Schematic representation of the *LRP5* genomic region showing the locations of SNPs.

Coding and noncoding sequences of exons are shown as closed and open boxes, respectively. Details of the SNPs are provided in Table 4. (B) Values of D' (bold type) and of r^2 (nonbold type) for pairwise LD analysis in 92 control subjects. Two estimated LD blocks are highlighted in gray.

Table 1. Association analysis for SNPs of *LRP6* and Type 2 DM in the initial panel.

Position on chromosome 12	SNP name	rs number	Major allele	Minor allele	MAF Case	MAF Control	P value	Odds ratio (95% CI)
12314360	SNP6-1	rs7136900	G	A	0.08	0.10	0.042*	0.72 (0.52–0.99)
12304062	SNP6-2	rs10743980	C	T	0.19	0.23	0.019*	0.77 (0.61–0.96)
12279248	SNP6-3	rs7956971	T	C				
12267732	SNP6-4	rs11054731	G	A	0.28	0.31	0.106	
12256592	SNP6-5	rs17302049	A	G	0.22	0.20	0.241	
12253186	SNP6-6	rs1181332	A	G	0.05	0.05	0.837	
12241380	SNP6-7	rs2417086	A	G	0.19	0.24	0.008*	0.74 (0.59–0.93)
12224619	SNP6-8	rs10492120	C	T				
12222642	SNP6-9	rs2417085	T	C	0.16	0.18	0.186	
12214885	SNP6-10	rs7294695	G	C	0.19	0.21	0.293	
12193165	SNP6-11	rs2302685	T	C	0.06	0.05	0.333	
12166202	SNP6-12	rs2284396	C	T	0.18	0.22	0.094	
12159793	SNP6-13	rs7316466	T	C	0.16	0.16	0.984	

SNP position is indicated as base-pair number in NCBI build 127. MAF, minor allele frequency. P values for the difference in the minor allele frequency between cases and controls were calculated by the chi-square test; the odds ratio and 95% confidence interval (CI) were also calculated for the minor allele. Asterisks indicate P values of <0.05.

Table 2. Association analysis for rs2417086 (SNP6-7) and rs17302049 (SNP6-5).

dbSNP ID	Initial panel								Replication panel												
	<i>n</i>		MAF		OR (95% CI)	<i>P</i>	<i>n</i>		MAF		OR (95% CI)	<i>P</i>	<i>n</i>		MAF		OR (95% CI)	<i>P</i>			
	Case	Control	Case	Control			Case	Control	Case	Control			Case	Control	Case	Control					
rs2417086	AA	400	215	0.19	0.24	0.74	0.008*	305	336	0.23	0.22	1.06	0.569								
	AG	188	128			(0.59-0.93)		167	175			(0.86-1.31)									
	GG	20	23					30	29												
rs17302049	AA	364	231	0.22	0.20	1.15	0.241	322	329	0.22	0.23	0.92	0.451								
	AG	214	113			(0.91-1.44)		170	188			(0.75-1.13)									
	GG	29	16					28	33												
Combined																					
<i>n</i>		MAF		OR (95% CI)		<i>P</i>		<i>n</i>		MAF		OR (95% CI)		<i>P</i>		<i>n</i>		MAF		OR (95% CI)	
Case	Control	Case	Control					Case	Control	Case	Control					Case	Control	Case	Control		
705	551	0.21	0.22	0.89		0.130															
355	303			(0.77-1.03)																	
50	52																				
686	560	0.22	0.22	1.01	0.895																
384	301			(0.87-1.17)																	
57	49																				

MAF, minor allele frequency. *P* values for the difference in the minor allele frequency between cases and controls were calculated by the chi-square test; the odds ratio and 95% confidence interval (CI) were also calculated for the minor allele. Asterisks indicate *P* values of <0.05.

Table 3. Clinical characteristics of Type 2 DM subjects in the initial panel according to genotype for rs2417086 (SNP6-7) of LRP6.

Parameter	AA	AG	GG	P value
Sex (male/female)	234/166	107/81	8/12	
Age (years)	61 ± 10 (<i>n</i> = 400)	61 ± 10 (<i>n</i> = 188)	59 ± 12 (<i>n</i> = 20)	0.710
BMI (kg/m ²)	23.8 ± 3.5 (<i>n</i> = 399)	23.9 ± 3.3 (<i>n</i> = 188)	25.0 ± 4.5 (<i>n</i> = 20)	0.245
FPG (mmol/l)	7.7 ± 2.5 (<i>n</i> = 307)	7.5 ± 2.0 (<i>n</i> = 139)	8.2 ± 2.8 (<i>n</i> = 19)	0.285
HOMA-IR*	2.90 ± 2.39 (<i>n</i> = 299)	3.14 ± 3.32 (<i>n</i> = 136)	2.79 ± 2.06 (<i>n</i> = 19)	0.920
HOMA-β*	54.0 ± 95.4 (<i>n</i> = 298)	60.5 ± 80.2 (<i>n</i> = 133)	44.3 ± 50.3 (<i>n</i> = 19)	0.342
Total cholesterol (mmol/l)*	5.3 ± 1.0 (<i>n</i> = 271)	5.2 ± 1.0 (<i>n</i> = 119)	5.4 ± 0.6 (<i>n</i> = 15)	0.614
HDL-cholesterol (mmol/l)*	1.4 ± 0.4 (<i>n</i> = 269)	1.4 ± 0.4 (<i>n</i> = 118)	1.3 ± 0.4 (<i>n</i> = 15)	0.832
LDL-cholesterol (mmol/l)*	3.3 ± 0.9 (<i>n</i> = 267)	3.2 ± 0.9 (<i>n</i> = 116)	3.3 ± 0.5 (<i>n</i> = 14)	0.689
Triglyceride (mmol/l)*	1.4 ± 0.8 (<i>n</i> = 271)	1.7 ± 2.6 (<i>n</i> = 119)	1.8 ± 1.3 (<i>n</i> = 15)	0.302
HbA _{1c} (%)*	8.0 ± 1.9 (<i>n</i> = 400)	7.7 ± 1.7 (<i>n</i> = 187)	7.7 ± 1.7 (<i>n</i> = 20)	0.312

Data are means ± SD. *P* values were calculated by ANOVA. *These parameters were log transformed before analysis.


Table 4. Association analysis for SNPs of *LRP5* and Type 2 DM in the initial panel.

Position on Chromosome 11	SNP name	rs number	Major allele	Minor allele	MAF		<i>P</i> value
					Case	Control	
67838979	SNP5-1	rs312016	C	T	0.48	0.48	0.920
67845407	SNP5-2	rs4988300	G	T	0.25	0.24	0.626
67857932	SNP5-3	rs7944040	C	T	0.14	0.15	0.584
67897990	SNP5-4	rs638051	A	G	0.26	0.28	0.442
67920032	SNP5-5	rs4930573	C	G	0.22	0.23	0.591
67938604	SNP5-6	rs314750	A	G	0.33	0.36	0.244
67949266	SNP5-7	rs556442	A	G	0.37	0.40	0.171
67957871	SNP5-8	rs3736228	C	T	0.29	0.30	0.587
67966294	SNP5-9	rs3781579	T	C	0.16	0.16	0.820

SNP position is indicated as base-pair number in NCBI build 127. MAF, minor allele frequency. *P* values for the difference in the minor allele frequency between cases and controls were calculated by the chi-square test.

Figure 1 Zenibayashi et al

A.




B.

D' \ r ²	SNP6-1	SNP6-2	SNP6-3	SNP6-4	SNP6-5	SNP6-6	SNP6-7	SNP6-8	SNP6-9	SNP6-10	SNP6-11	SNP6-12	SNP6-13
SNP6-1	0.20	0.19	0.08	0.00	0.39	0.20	0.00	0.00	0.13	0.16	0.13	0.00	
SNP6-2	0.75		1.00	0.60	0.09	0.18	0.94	0.64	0.64	0.61	0.11	0.58	0.32
SNP6-3	0.73	1.00		0.60	0.09	0.19	0.94	0.66	0.66	0.60	0.11	0.58	0.33
SNP6-4	0.56	0.93	0.93		0.12	0.08	0.60	0.35	0.35	0.38	0.02	0.36	0.18
SNP6-5	-0.19	-1.00	-1.00		0.02	0.09	0.06	0.06	0.06	0.06	0.01	0.06	0.03
SNP6-6	0.88	-1.00	-1.00	0.79	-1.00	0.18	0.13	0.13	0.14	0.52	0.13	0.10	
SNP6-7	0.75	0.97	0.97	0.93	-1.00	1.00	0.64	0.64	0.56	0.11	0.53	0.31	
SNP6-8	0.02	0.96	0.96	0.85	-1.00	0.71	0.96	1.00	0.31	0.16	0.30	0.52	
SNP6-9	0.02	0.96	0.96	0.85	-1.00	0.71	0.96	1.00	0.31	0.16	0.30	0.52	
SNP6-10	0.58	0.80	0.80	0.76	-0.82	0.84	0.77	0.65	0.65		0.12	0.97	0.62
SNP6-11	0.60	0.80	0.80	0.45	-1.00	0.76	0.80	0.84	0.84	0.82		0.17	0.26
SNP6-12	0.58	0.78	0.77	0.73	-0.81	0.84	0.74	0.65	0.65	1.00	1.00		0.66
SNP6-13	-0.13	0.71	0.71	0.65	-0.71	0.57	0.70	0.75	0.75	0.95	1.00		1.00

Figure 2 Zenibayashi et al

A.



B.

D' \ r ²	SNP5-1	SNP5-2	SNP5-3	SNP5-4	SNP5-5	SNP5-6	SNP5-7	SNP5-8	SNP5-9
SNP5-1	0.27	0.12	0.07	0.00	0.00	0.00	0.00	0.00	0.00
SNP5-2	0.97	0.48	0.08	0.00	0.03	0.03	0.01	0.00	0.00
SNP5-3	-0.86	0.91		0.17	0.01	0.02	0.03	0.00	0.01
SNP5-4	-0.44	0.31	0.60		0.01	0.00	0.00	0.01	0.01
SNP5-5	0.09	-0.07	0.15	0.13		0.20	0.15	0.21	0.13
SNP5-6	0.06	0.24	0.26	0.07	0.61		0.78	0.57	0.22
SNP5-7	0.00	0.26	0.34	0.09	0.59	0.97		0.62	0.25
SNP5-8	0.05	0.12	0.10	0.08	0.54	0.86	0.98		0.14
SNP5-9	-0.09	-0.08	0.08	-0.32	0.46	0.80	0.94	0.57	